BIOM


Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
Related to BIOM: BOM
AcronymDefinition
BIOMBiomira Inc. (stock symbol)
BIOMBinocular Indirect OphthalmoMicroscope (wide angle viewing system)
BIOMBiometrisches Merkmal (biometrics)
References in periodicals archive ?
BioMS is conducting ongoing pivotal clinical trials evaluating the ability of dirucotide to affect disease progression in patients with secondary progressive MS:
Under the terms of the agreement, Lilly and BioMS Medical will collaborate on
It also provides a view into the excellent scientific and clinical development supporting this important MS drug," said Kevin Giese, president and CEO of BioMS Medical.
The larger study seeks to "confirm the encouraging clinical results obtained with this novel treatment approach," reported the authors, who are from the Multiple Sclerosis Patient Care and Research Clinic in the division of neurology at the University of Alberta, Edmonton, and from BioMS Medical (Eur.
He is the founding President of BioMS Medical, and has been in senior management roles and on the board of directors of a number of private and publicly listed companies.
We are very encouraged by the safety board's recommendation," said Kevin Giese, President and CEO of BioMS Medical.
is a significant step towards bringing MBP8298 to the worldwide market," said Kevin Giese, president and CEO of BioMS Medical.
Securing FDA approval to conduct this pivotal US trial is a major milestone in the advancement of Toraymyxin(TM), a product with blockbuster potential and a track record of safety and efficacy in the treatment of severe sepsis," said Kevin Giese, President and CEO of BioMS Medical Corp.
The clearance to proceed with a phase III trial in the US is a significant step towards bringing MBP8298 to the worldwide market," said Kevin Giese, President and CEO of BioMS Medical.
The resources from this investment, combined with the clinical, regulatory and capital market expertise of the BioMS team, will assist Spectral to effectively conduct its anticipated pivotal trial in the US.
We are pleased to have reached this major milestone in this very important study," said Kevin Giese, President and CEO of BioMS Medical.
BioMS has decided that it will explore a compassionate access and research program with limited financial commitment, but that it will not pursue further late stage clinical trials with dirucotide in MS.